Literature DB >> 1322787

In vitro activation of distinct molecular and cellular phenotypes after induction of differentiation in a human neuroblastoma cell line.

C Gaetano1, K Matsumoto, C J Thiele.   

Abstract

In this report we provide evidence for the activation of distinct differentiation pathways during treatment of the neuroblastoma cell line SMS-KCNR with 1 mM dibutyryl cyclic AMP (dbcAMP) and/or 5 microM retinoic acid (RA). Our results show that the adrenal gland specific gene pG2 is induced only during dbcAMP treatment, while RA induces a neuronal phenotype and expression of all neural related genes while decreasing the expression of many chromaffin related genes. Furthermore dbcAMP does not affect the DNA content distribution of SMS-KCNR [G1 = 61.8 +/- 4.1% (SD); S = 20.3 +/- 6.3%; G2-M = 18 +/- 5.4%] despite morphological and molecular signs of cellular differentiation. Conversely, RA arrests cell growth causing a decrease in cells in the growth fraction (S + G2 + M = 15.6 +/- 6.1%) and an increase in cells in G1 (G1 = 84.3 +/- 5%). Using cyclic AMP and RA in combination, we found that RA inhibited expression of adrenal gland specific gene pG2 and induced a neuronal phenotype. Since dbcAMP does not cause a significant G1 block in SMS-KCNR cells we propose that this agent may be able to induce SMS-KCNR only to an intermediate stage of chromaffin differentiation in which cells retain their proliferative potential.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322787

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  CASZ1 inhibits cell cycle progression in neuroblastoma by restoring pRb activity.

Authors:  Zhihui Liu; Julieann Rader; Stanley He; Tanya Phung; Carol J Thiele
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

2.  Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced normalization of brain retinoid signaling.

Authors:  N Etchamendy; V Enderlin; A Marighetto; R M Vouimba; V Pallet; R Jaffard; P Higueret
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

3.  In vivo spontaneous neuronal to neuroendocrine lineage conversion in a subset of neuroblastomas.

Authors:  C Gestblom; J C Hoehner; F Hedborg; B Sandstedt; S Påhlman
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

4.  Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells.

Authors:  Manrong Jiang; Kejin Zhu; Jose Grenet; Jill M Lahti
Journal:  Biochim Biophys Acta       Date:  2008-03-10

5.  Retinoic acid negatively regulates beta 4 integrin expression and suppresses the malignant phenotype in a Lewis lung carcinoma cell line.

Authors:  C Gaetano; A Melchiori; A Albini; R Benelli; R Falcioni; A Modesti; A Modica; S Scarpa; A Sacchi
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

Review 6.  Epigenetic changes in pediatric solid tumors: promising new targets.

Authors:  Elizabeth R Lawlor; Carol J Thiele
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

7.  Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma.

Authors:  Kwang Woon Kim; Julia Y Kim; Jingbo Qiao; Rachael A Clark; Camille M Powers; Hernan Correa; Dai H Chung
Journal:  Oncotarget       Date:  2019-09-24

Review 8.  Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives.

Authors:  Paolo Romania; Alice Bertaina; Giorgia Bracaglia; Franco Locatelli; Doriana Fruci; Rossella Rota
Journal:  Int J Mol Sci       Date:  2012-12-05       Impact factor: 5.923

9.  Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.

Authors:  Caroline E Nunes-Xavier; Olaia Aurtenetxe; Laura Zaldumbide; Ricardo López-Almaraz; Asier Erramuzpe; Jesús M Cortés; José I López; Rafael Pulido
Journal:  Diagn Pathol       Date:  2019-12-14       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.